Description References
ChemicalBook > CAS DataBase List > Vipadenant

Vipadenant

Description References
Vipadenant Structure
Vipadenant
  • CAS No.442908-10-3
  • Chemical Name:Vipadenant
  • CBNumber:CB52627600
  • Molecular Formula:C16H15N7O
  • Formula Weight:321.34
  • MOL File:442908-10-3.mol
Vipadenant Property
  • Melting point 245.3-246.1 °C
  • Boiling point 668.5±65.0 °C(Predicted)
  • Density 1.56±0.1 g/cm3(Predicted)
  • storage temp. Store at -20°C
  • solubility DMSO:37.0(Max Conc. mg/mL);115.14(Max Conc. mM)
  • form A crystalline solid
  • pka 4.27±0.30(Predicted)
  • color Light yellow to yellow
  • FDA UNII LDR3USH1NJ
Safety
Hazard and Precautionary Statements (GHS)
  • Symbol(GHS)
  • Signal wordWarning
  • Hazard statements H302-H400-H410
  • Precautionary statements P264-P270-P273-P301+P312-P330-P391-P501

Vipadenant Chemical Properties,Usage,Production

  • Description Vipadenant (also known as BIIB014) is a potent, selective oral adenosine A2A receptor antagonist under development for the treatment of Parkinson’s disease. It has successfully completed phase I clinical studies. It might also be a potential adjunctive therapy reagent for cancer treatment. It was found that it has certain potentials to disrupt an immunosuppressive mechanism of tumour protection, generating improved efficacy for immunotherapies of certain cancers when used in combination with other drugs.
  • References http://www.medkoo.com/products/8047
    Shook, B. C., and P. F. Jackson. "Adenosine A(2A) Receptor Antagonists and Parkinson's Disease. " Acs Chemical Neuroscience2.10(2011):555-67.
    Brooks, D. J., et al. "An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers." Clinical Neuropharmacology 33.2(2010):55.
    http://www.vernalis.com/nce-pipeline/oncology/v2006
  • Uses Vipadenant is a potent, selective and orally available adenosine A2A receptor antagonist under development for for Parkinson''s disease. Vipadenant demonstrates strong oral activity in commonly used models of Parkinson''s disease. Vipadenant has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies.
  • in vivo

    Vipadenant (0.3-30 mg/kg) produces a dose-dependent reduction in catalepsy. Vipadenant (10 mg/kg) does not produce any statistically significant dyskinetic episodes in 6-OHDA-lesioned rats during a 19-day dosing regimen[1]. In the mouse and rat haloperidol-induced hypolocomotion models, vipadenant has a minimum effective dose of 0.1 and 1 mg/kg, respectively. Vipadenant (3 and 10 mg/kg, p.o.) is able to increase contralateral rotations in 6-OHDA lesioned rats[2].

Vipadenant Preparation Products And Raw materials
Raw materials
Preparation Products
Vipadenant Suppliers
Global(77)Suppliers
  • Supplier：
    BOC Sciences
  • Tel：+1-631-485-4226
  • Email：inquiry@bocsci.com
  • Country：United States
  • ProdList：19552
  • Advantage：58
  • Supplier：
    career henan chemical co
  • Tel：+86-0371-86658258<br/>+8613203830695
  • Email：factory@coreychem.com
  • Country：China
  • ProdList：29808
  • Advantage：58
  • Supplier：
    TargetMol Chemicals Inc.
  • Tel：+1-781-999-5354<br/>+1-00000000000
  • Email：marketing@targetmol.com
  • Country：United States
  • ProdList：32159
  • Advantage：58
  • Supplier：
    InvivoChem
  • Tel：+1-708-310-1919<br/>+1-13798911105
  • Email：sales@invivochem.cn
  • Country：United States
  • ProdList：6391
  • Advantage：58
  • Supplier：
    LEAP CHEM CO., LTD.
  • Tel：+86-852-30606658
  • Email：market18@leapchem.com
  • Country：China
  • ProdList：24727
  • Advantage：58
Vipadenant Spectrum
442908-10-3, VipadenantRelated Search:
  • API
  • Inhibitors
  • 抑制剂
  • 生物试剂
  • 小分子抑制剂
  • 小分子抑制剂，天然产物
  • C16H15N7O
  • 化合物VIPADENANT,10 MM DMSO 溶液
  • 3-(4-氨CHEMICALBOOK基-3-甲基并苄基)-7-(2-呋喃基)-3H-[1,2,3]噻唑并[4,5-D]嘧啶-5-胺
  • 化合物VIPADENANT
  • 3-(4-氨基-3-甲基并苄基)-7-(2-呋喃基)-3H-[1,2,3]噻唑并[4,5-D]嘧啶-5-胺
  • 3-(4-氨基-3-甲基苄基)-7-(呋喃-2-基)-3H-[1,2,3]三唑并[4,5-D]嘧啶-5-胺
  • 442908-10-3
  • Vipadenant, 10 mM in DMSO
  • BIIB-014, CEB-4520
  • CEB 4520,Vipadenant,BIIB 014,BIIB014,CEB4520,inhibit,Adenosine Receptor,Inhibitor,P1 receptor
  • 3-(4-AMINO-3-METHYLBENZYL)-7-(FURAN-2-YL)-3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDIN-5- AMINE
  • 3-[(4-amino-3-methylphenyl)methyl]-7-(furan-2-yl)triazolo[4,5-d]pyrimidin-5-amine
  • CS-2294
  • BIIB-014;BIIB 014;BIIB014
  • BIIB-014 Vipadenant
  • 3H-1,2,3-Triazolo[4,5-d]pyrimidin-5-amine, 3-[(4-amino-3-methylphenyl)methyl]-7-(2-furanyl)-
  • 5-BROMO-4-(METHYLSULFANYL)-1H-PYRROLO[2,3-B]PYRIDINE
  • Vipadenant
  • BIIB 014
  • VER-ADO 49
  • VER-A 00-11
  • VER-A 00049
  • VER 11135
  • V 2006
  • CEB 4520
  • 3-[(4-Amino-3-methylphenyl)methyl]-7-(2-furanyl)-3H-1,2,3-triazolo[4,5-d]pyrimidin-5-amine
  • Vipadenant(BIIB 014)

Home

My